Sami Khella, MD
Neurology · Philadelphia, PANPI 1124011473
Payments from drug & device makers
Across 425 payments — averaging $3375.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Catalyst Pharmaceuticals, Inc.$287K
- Novartis$270K
- Argenx US, Inc.$250K
- AstraZeneca$204K
- Regeneron$139K
- Akcea Therapeutics, Inc.$112K
- plus $172K from 16 others
Across 8 payments — averaging $171.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$1K
What the payments were for
- Consulting fees$113,22340%
- Speaking & faculty fees$115,13340%
- Travel & lodging$48,44217%
- Food & beverage$7,9443%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Catalyst Pharmaceuticals, Inc. | 9 | $287,215 |
| Novartis | 6 | $270,043 |
| Argenx US, Inc. | 89 | $249,872 |
| AstraZeneca(2 entities) | 44 | $204,045 |
| Regeneron | 60 | $138,725 |
| Akcea Therapeutics, Inc. | 100 | $112,304 |
| Pfizer | 27 | $101,555 |
| CSL Behring | 38 | $43,571 |
| Alnylam Pharmaceuticals Inc. | 23 | $9,793 |
| Grifols USA, LLC | 4 | $4,156 |
| Amgen | 3 | $3,418 |
| UCB, Inc. | 7 | $2,776 |
| Swedish Orphan Biovitrum AB | 1 | $2,425 |
| Sobi, Inc | 1 | $2,400 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,380 |
| Astrazeneca UK Limited | 1 | $650 |
| AbbVie | 5 | $110 |
| SK Life Science, Inc. | 1 | $33 |
| Lilly USA, LLC | 2 | $29 |
| Biogen | 1 | $22 |
| Kedrion Biopharma, Inc. | 1 | $14 |
| Tanabe Pharma America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,434,546 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UltomirisRavulizumab-Cwvz | 116 | $4,724,354 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 407 | $4,398,683 |
| AmvuttraVutrisiran Sodium | 28 | $3,395,520 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 278 | $2,810,337 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 120 | $1,724,351 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 66 | $988,508 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 96 | $774,549 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 92 | $700,023 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 32 | $527,180 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 45 | $441,222 |
| XembifyImmune Globulin,gamma(Igg)klhw | 36 | $396,446 |
| FingolimodFingolimod Hcl | 30 | $64,596 |
| Emgality PenGalcanezumab-Gnlm | 16 | $11,370 |
| Mycophenolate Mofetil | 89 | $10,348 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 24 | $9,193 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen, Hizentra | $43,571 | $4,839,905452 claims |
| AstraZenecaUltomiris | $204,045 | $4,724,354116 claims |
| Alnylam Pharmaceuticals Inc.Amvuttra | $9,793 | $3,395,52028 claims |
| Kedrion Biopharma, Inc.Gammaked | $14 | $2,810,337278 claims |
| PfizerOctagam, Panzyga | $101,555 | $2,251,530152 claims |
| Grifols USA, LLCGamunex-C, Xembify | $4,156 | $1,096,469128 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $1,380 | $774,54996 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Philadelphia
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Daniel KremensPhiladelphia$1.9M
- Frances JensenPhiladelphia$1.8M
- Andres Deik Acosta MadiedoPhiladelphia$1.8M
- Michael SperlingPhiladelphia$1.7M
- Sanjeev VaishnaviPhiladelphia$1.6M
- Andrew SiderowfPhiladelphia$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.